BRIEF: Hutchmed’s revenue drops 13% in 2025
Drug developer Hutchmed China Ltd. (HCM.US; 0013.HK) said on Thursday its revenue fell 13% in 2025 to $548.5 million from $630.2 million the previous year, as its profit rose sharply…
BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for…
Will Trump’s drug order put the brakes on China’s overseas pharma drive?
The U.S. president has promised to reduce prescription drug prices by 30% to 80% for Americans, insisting they are entitled to prices paid in other developed countries Key Takeaways: Pharma…
BRIEF: Hutchmed profit falls on shrinking R&D income
Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results…
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
The drug maker is selling most of its stake in a joint venture with Shanghai Pharmaceuticals for $608 million By Teri Yu Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), the biopharmaceutical…
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
The biotech company’s merger with Ikena Oncology will bring in $175 million in fresh funds, including $75 million from an oversubscribed private placement Key Takeaways: Inmagene Bio plans to merge…
Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
Recent Articles
BRIEF: Hutchmed’s revenue drops 13% in 2025
HCM.US
0013.HK
BRIEF: Hutchmed’s revenue falls in first half of 2025
0013.HK
HCM.US
BRIEF: Hutchmed profit falls on shrinking R&D income
0013.HK
HCM.US
